Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)

B. C. Cho; J. Lin; D. R. Camidge; V. Velcheti; B. Solomon; S. Lu; K. H. Lee; S. W. Kim; S. Kao; R. Diadziuskzko; M. Beg; M. Nagasaka; E. Felip; B. Besse; C. Springfeld; S. Popat; J. Wolf; D. Trone; S. Stopatschinskaja; A. Drilon

doi:10.1016/S0959-8049(22)00812-7

Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)

B. C. Cho, J. Lin, D. R. Camidge, V. Velcheti, B. Solomon, S. Lu, K. H. Lee, S. W. Kim, S. Kao, R. Diadziuskzko, M. Beg, M. Nagasaka, E. Felip, B. Besse, C. Springfeld, S. Popat, J. Wolf, D. Trone, S. Stopatschinskaja, A. Drilon

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

8 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	S1-S2
journal	European Journal of Cancer
Volume	174
Les DOIs	https://doi.org/10.1016/S0959-8049(22)00812-7
état	Publié - 1 oct. 2022

Accès au document

10.1016/S0959-8049(22)00812-7

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Cho, B. C., Lin, J., Camidge, D. R., Velcheti, V., Solomon, B., Lu, S., Lee, K. H., Kim, S. W., Kao, S., Diadziuskzko, R., Beg, M., Nagasaka, M., Felip, E., Besse, B., Springfeld, C., Popat, S., Wolf, J., Trone, D., Stopatschinskaja, S., & Drilon, A. (2022). Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC). European Journal of Cancer, 174, S1-S2. https://doi.org/10.1016/S0959-8049(22)00812-7

@article{bbc0d60ff9274a06a0e17480a6623e7f,

title = "Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)",

author = "Cho, {B. C.} and J. Lin and Camidge, {D. R.} and V. Velcheti and B. Solomon and S. Lu and Lee, {K. H.} and Kim, {S. W.} and S. Kao and R. Diadziuskzko and M. Beg and M. Nagasaka and E. Felip and B. Besse and C. Springfeld and S. Popat and J. Wolf and D. Trone and S. Stopatschinskaja and A. Drilon",

year = "2022",

month = oct,

day = "1",

doi = "10.1016/S0959-8049(22)00812-7",

language = "English",

volume = "174",

pages = "S1--S2",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

Cho, BC, Lin, J, Camidge, DR, Velcheti, V, Solomon, B, Lu, S, Lee, KH, Kim, SW, Kao, S, Diadziuskzko, R, Beg, M, Nagasaka, M, Felip, E, Besse, B, Springfeld, C, Popat, S, Wolf, J, Trone, D, Stopatschinskaja, S & Drilon, A 2022, 'Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)', European Journal of Cancer, VOL. 174, p. S1-S2. https://doi.org/10.1016/S0959-8049(22)00812-7

TY - JOUR

T1 - Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)

AU - Cho, B. C.

AU - Lin, J.

AU - Camidge, D. R.

AU - Velcheti, V.

AU - Solomon, B.

AU - Lu, S.

AU - Lee, K. H.

AU - Kim, S. W.

AU - Kao, S.

AU - Diadziuskzko, R.

AU - Beg, M.

AU - Nagasaka, M.

AU - Felip, E.

AU - Besse, B.

AU - Springfeld, C.

AU - Popat, S.

AU - Wolf, J.

AU - Trone, D.

AU - Stopatschinskaja, S.

AU - Drilon, A.

PY - 2022/10/1

Y1 - 2022/10/1

UR - http://www.scopus.com/inward/record.url?scp=85140460065&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(22)00812-7

DO - 10.1016/S0959-8049(22)00812-7

M3 - Article

AN - SCOPUS:85140460065

SN - 0959-8049

VL - 174

SP - S1-S2

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -